A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)

Hiddo J. L Heerspink¹, Donald E. Kohan², Richard A. Lafayette³, Adeera Levin⁴, Hong Zhang⁵, Andrew J. King⁶, Alan Glicklich⁶, Jonathan Barratt⁷

¹. University Medical Center Groningen, Groningen, Netherlands. ². University of Utah Health, Salt Lake City, UT, United States. ³. Stanford Medicine, Stanford, CA, United States. ⁴. The University of British Columbia Faculty of Medicine, Vancouver, BC, Canada. ⁵. Peking University First Hospital, Beijing, Beijing, China. ⁶. Chinook Therapeutics, Seattle, WA. ⁷. University of Leicester Medical School, Leicester, Leicester, United Kingdom.
## Author Disclosures

<table>
<thead>
<tr>
<th>Category</th>
<th>Disclosure Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current Employer</td>
<td>University Medical Center Groningen</td>
</tr>
<tr>
<td>Consultancy Agreements</td>
<td>Ongoing consultancy agreements with Astra-Zeneca, Bayer, Boehringer Ingelheim, Chinook Therapeutics, CSL Pharma, Gilead, Janssen, Merck, MundiPharma, Mitsubishi Tanabe and Retrophin</td>
</tr>
<tr>
<td>Ownership Interest</td>
<td>Nothing to disclose.</td>
</tr>
<tr>
<td>Research Funding</td>
<td>Abbvie, Astra Zeneca, Boehringer Ingelheim and Janssen research support (honoraria directed to employer)</td>
</tr>
<tr>
<td>Honoraria</td>
<td>Nothing to disclose.</td>
</tr>
<tr>
<td>Patents and Inventions</td>
<td>Nothing to disclose.</td>
</tr>
<tr>
<td>Scientific Advisor or Membership</td>
<td>Nothing to disclose.</td>
</tr>
<tr>
<td>Speakers Bureau</td>
<td>Speaker bureau for AstraZeneca.</td>
</tr>
<tr>
<td>Other Interests/Relationships</td>
<td>Nothing to disclose.</td>
</tr>
</tbody>
</table>

The ALIGN Trial is sponsored by Chinook Therapeutics, Inc.
Study Background – Atrasentan

- Atrasentan is a potent endothelin A (ET$_A$) receptor antagonist (Ki = 0.034 nM) with >1,800 fold selectivity over ET$_B$ (Ki = 63.3 nM).\[^1\]
- Blocking ET$_A$ leads to rapid and sustained reductions in proteinuria and has direct anti-inflammatory and anti-fibrotic effects.\[^2\]
- Atrasentan has been studied extensively in more than 5,300 patients with type 2 diabetes and kidney disease (DKD), demonstrating clinically significant and sustained reductions in proteinuria when administered on top of a maximum tolerated dose of a RAS inhibitor (RASI).\[^3,4\]
- In a Phase 2 study in DKD (RADAR), atrasentan reduced urine albumin-creatinine ratios by an average of 35% (95% confidence interval [CI]: 24, 45; P = 0.001).\[^3\]
- In a global Phase 3 outcome study in DKD (SONAR), the atrasentan treatment group demonstrated a 35% reduced risk of the primary composite outcome of doubling serum creatinine or end stage kidney disease (95% CI: 0.49, 0.88; P = 0.005).\[^4\]
Study Background – IgA Nephropathy

IgA nephropathy (IgAN) is the most common primary glomerulonephritis globally and an important cause of chronic kidney disease (CKD). Up to 45% of IgAN patients are at risk of progressing to end-stage kidney disease (ESKD) and proteinuria is the strongest predictor of progression. [5,6]

There are no approved therapies for IgAN and no clear consensus on second line therapy to manage residual proteinuria despite maximally tolerated RAS inhibition. [KDIGO, 2012]

Immunosuppression, with steroids or other agents has been studied extensively; however, the efficacy of immunosuppression is inconsistent and is associated with significant safety and tolerability concerns, leaving an important need for new strategies to lower proteinuria and preserve kidney function in high risk patients [7,8]
Rationale for Atrasentan Use in IgA Nephropathy

- ET$_A$ activation results in mesangial cell collagen and cytokine production$^{[9]}$, podocyte injury$^{[10]}$, proteinuria$^{[4]}$ and tubulointerstitial inflammation and fibrosis$^{[12]}$, all hallmark characteristics of progressive IgAN.

- The use of selective ET$_A$ blockade in IgAN has been clinically validated in an exploratory trial of sitaxsentan demonstrating significant reduction in proteinuria and intraglomerular pressure in CKD patients on standard of care therapy$^{[13]}$. 

---

**IgAN Disease Pathophysiology**

- **Hit 1**: Increased levels of Gd-IgA1
- **Hit 2**: Production of anti-Gd-IgA1 autoantibodies
- **Hit 3**: Formation of circulating nephritogenic Gd-IgA1 immune complexes
- **Hit 4**: Mesangial deposition and glomerular injury, Cellular proliferation, Overproduction of extracellular matrix, cytokines and chemokines

**Atrasentan**

- Mesangial cell
- Protein
- T cell
- Macrophage
- Monocyte
- Podocyte
- IgA
- Gd-IgA1
- IgG
Proteinuria as a Surrogate Endpoint for Accelerated Approval

Proteinuria is the single most important predictor of the rate of renal progression in IgAN [6].

Trial-level analyses of data from 13 randomized-controlled trials show a strong association between treatment effects on proteinuria with hard renal outcomes in IgAN [14].

Proteinuria reduction is recognized as a reasonably likely surrogate endpoint by the FDA to support accelerated regulatory approval [14].
Study Objectives

The Phase 3 ALIGN trial will assess the efficacy, safety and tolerability of atrasentan in IgAN patients at risk of progressive kidney function loss, despite optimized RAS blockade.

Study Endpoints

The primary endpoint for the ALIGN study is change in proteinuria (UPCR from a 24-hr urine collection) from baseline to week 24.

The key secondary endpoint for the study is change in eGFR from baseline to week 136 (4 weeks following discontinuation of treatment).

Additional secondary outcome measures include:

- Rate of change in eGFR during 2 years on treatment at Week 12 through to Week 120 and from baseline to Week 136.
- Percent of subjects achieving proteinuria < 1 g/day at Week 24 and 40% reduction in UPCR from baseline.
- Percent of subjects experiencing at least a 30% reduction in eGFR or reach ESKD during the study.
- Percent of subjects experiencing at least a 40% reduction in eGFR or reach ESKD during the study.

Study Design

Approximately 320 patients across North America, South America, Europe, and Asia-Pacific with biopsy-proven IgAN will be randomized to receive 0.75 mg atrasentan or placebo daily for 132 weeks.

Patients will receive a maximally tolerated and stable dose of a RASi.

- The study will include a cohort of patients who are unable to tolerate RASi.

Subjects will have assessments of safety and efficacy over 2½ years

- Where allowed by local regulations, options for remote study visits using telemedicine and home health may be offered.
- Provides a flexible solution for patients and clinicians in the era of COVID-19 and reduces the burden to patients for trial participation.

Subjects who complete the study may be eligible to enroll in an open-label treatment trial with atrasentan.
Key Eligibility Criteria

- Age 18 and older
- Biopsy proven IgAN - no time limit on biopsy
- Stable, optimized dose of ACE inhibitor or ARB for ≥ 12 weeks - a cohort of patients unable to tolerate RASi will be included
- UPCR ≥ 1 g/g based on first morning void
- eGFR of at least 30 mL/min/1.73m²
- No use of systemic immunosuppressants, such as steroids, for more than 2 weeks in the past 3 month
- No current diagnosis with another chronic kidney disease, including diabetic kidney disease
- No history of kidney or other transplantation
- No history of heart failure or a previous hospital admission for fluid overload

Virtual trial options may include telemedicine and home health nurse visits
Patient compensation for 24-hour urine collection and reimbursement for trial-related expenses

Open label extension study available to participants completing the study
Currently selecting trial sites in North America, South America, Europe, and Asia-Pacific. Enrollment begins in January 2021

ClinicalTrials.gov Identifier: NCT04573478
References


